ImmuDyne Inc (IMMD) Insider Purchases $138,000.00 in Stock

ImmuDyne Inc (OTCMKTS:IMMD) insider Justin Schreiber purchased 600,000 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was bought at an average price of $0.23 per share, with a total value of $138,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Justin Schreiber also recently made the following trade(s):

  • On Monday, December 4th, Justin Schreiber purchased 24,867 shares of ImmuDyne stock. The stock was bought at an average price of $0.39 per share, with a total value of $9,698.13.

Shares of ImmuDyne Inc (IMMD) traded down $0.00 on Monday, reaching $0.29. The company had a trading volume of 30,404 shares, compared to its average volume of 45,617. ImmuDyne Inc has a 12 month low of $0.22 and a 12 month high of $0.95.

ImmuDyne (OTCMKTS:IMMD) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($0.02) earnings per share (EPS) for the quarter.

COPYRIGHT VIOLATION NOTICE: “ImmuDyne Inc (IMMD) Insider Purchases $138,000.00 in Stock” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/immudyne-inc-immd-insider-purchases-138000-00-in-stock.html.

ImmuDyne Company Profile

Immudyne, Inc manufactures, distributes and sells natural immune support products. The Company’s products contain its yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. Its products include once a day oral intake tablets and topical creams and gels for skin application.

Receive News & Ratings for ImmuDyne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuDyne and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply